FDA authorizes software that can help identify prostate cancer
The Pharma Data
SEPTEMBER 30, 2021
Food and Drug Administration authorized marketing of software to help medical professionals who examine body tissues (pathologists) within the detection of areas that are suspicious for cancer as an adjunct (supplement) to the review of digitally-scanned slide images from prostate biopsies (tissue faraway from the body). Today, the U.S.
Let's personalize your content